Low-dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma  

作　　者：Yu-Pei Chen Jia-Yi Shen Zhen-Ji Deng Ying Sun Xiao-Yu Liang Jia-Wei Lv Jun Ma 

机构地区：[1]State Key Laboratory of Oncology in South China,Collaborative Innovation Center of Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,Center for Precision Medicine of Sun Yat-sen University,Sun Yat-sen University Cancer Center,Guangzhou,Guangdong 510060,P.R.China

出　　处：《Cancer Communications》2022年第10期909-912,共4页癌症通讯（英文）

基　　金：the National Natural Science Foundation of China(82172749);the Natural Science Foundation of Guangdong Province(2021B1515020010);the Fundamental Research Funds for the Central Universities,Sun Yat-sen University(22ykqb14).

摘　　要：1 BACKGROUND Nasopharyngeal carcinoma(NPC)is a unique head and neck malignancy prevalent in East Asia[1].It is highly malignant,with the non-keratinizing pathological subtype constituting approximately 95%of NPC cases in endemic areas.Chemotherapy in combination with radiotherapy is recommended for locoregionally advanced NPC(LANPC),especially in subgroups at higher risk of distant metastasis(e.g.,N2-3 vs.N0-1 diseases,high vs.low plasma Epstein-Barr virus[EBV]DNA copy number)[2,3].Concurrent chemoradiotherapy with or without induction chemotherapy is considered the backbone of the current chemoradiotherapy strategies for NPC[2,3].Nevertheless,although complete clinical remission could be achieved in more than 90%of patients after definitive chemoradiotherapy,about 20%-30%of patients will have disease recurrence subsequently[4,5],which might be caused minimal residual disease(MRD),either at locoregional or distant sites[6,7].Thus,adjuvant therapy is needed to improve tumor control.

关 键 词：CHEMOTHERAPY NASOPHARYNGEAL METASTASIS 

分 类 号：R739.63[医药卫生—肿瘤]